Objective-To apply an indirect m.ethod for estim.ation of the breast cancer related excess m.ortality in the Swedish random.ised m.am.m.ography screening trials. Setting-Random.ised trials on m.am.m.ography screening have, in Sweden, been perform.ed in the counties of Kopparberg (W) and Ostergotland (E), the so called WE study, and in the three largest cities in Sweden, Stockholm. (southern part), Gothenburg, and Malm.o. An overview of the trials was presented in the Lancet in 1993 and included 156911 wom.en in the invited group and 125 866 in the control group. Methods-The excess m.ortality in the breast cancer subgroups was estim.ated by indirect standardisation using official national cause of death statistics according to Statistics Sweden as a reference. Results-The estim.ated reduction of the breast cancer related m.ortality was 24% for the whole group (40-74 years at random.isation). The corresponding fig- ures for the age groups 40-49, 50-59, and 60-69 years were 6%, 28%, and 34% respectively. Conclusion-The results are very sim.ilar to those presented earlier based on the traditional com.parison of the breast cancer m.ortality in the invited and in the control group. This analysis further strengthens previous reports on a beneficial effect of m.am.m.ography screening, which is especially pronounced in the age group 50-69.
The ultimate goal of an intervention against a serious malignant disease, such as breast cancer, is usually to reduce the mortality. Besides being a basic goal, reduction of mortality is an objective measure of the efficacy of the intervention. If the effect on overall mortality is not obvious, randomised trials are needed.
In randomised trials of primary and adjuvant treatment the evaluation is relatively simple and is achieved by comparing the cumulative mortality (or its reversal, survival). Other measures, such as survival free from relapse, disease specific mortality, etc, can give additional information of clinical and biological interest but are less basic and also less objective.
In randomised trials of the effect of screening for early detection of cancer-for example breast cancer, evaluation is more complicated. Also, in such trials the total cumulative mortality would seem to be the most objective measure. However, as the studied cancer as a rule is responsible for only a small fraction of the total mortality such an approach would require very large cohorts and is therefore in practice impossible. Thus in women aged 40-69 in Sweden 1989 breast cancer was the underlying cause in only 9.4% of the deaths.' Therefore the effect of the randomised screening trials has been estimated by comparing the cumulative breast cancer mortality in the group invited to screening (invited group) with the group not invited to screening (control group).
The causes of death among the patients with breast cancer, diagnosed after the date of randomisation, have been determined either by record linkage to the national cause of death register":' or by a retrospective evaluation of the medical documentation, such as clinical records, necropsy protocols, histopathology reports, and cause of death certificates.?" An independent validation of the Swedish randomised trials on mammography screening has been completed."
However, individual identification of causes of death in the patients with breast cancer in invited and screening groups does not answer the question of how the invitation to screening influences the overall "excess mortality" caused, directly or indirectly, by breast cancer. In this paper, therefore, we have used an indirect method for estimating the breast cancer related excess mortality. This analysis obviates the need to determine whether or not breast cancer was the cause of death in each individual case.
The basic principle of the method is an indirect standardisation of the total mortality in the breast cancer subcohorts by comparing with a suitable reference population-that is, national cause of death statistics. In this paper the method and its application on the overview material from the Swedish randomised mammography screening trials is described. The results are also compared with results obtained by individual cause of death evaluation by an End Point Committee (EPC)" and by record linkage to the Swedish cause of death registry at the National Bureau of Statistics, Statistics Sweden.'
Material
The subjects in this study are identical to those presented in two previous reports ?" and comprised, after exclusion of breast cancer cases diagnosed before randomisation, 282 777 women included in four Swedish randomised mammography screening trials that started between 1976 and 1983 at five screening centres (Malmo, Kopparberg/Ostergotland (WE), Stockholm, and Gothenburg). The invited group included 156 911 and the control group 125866 women aged 40-74 at entry with an attendance rate of 85% in the invited group at the first screening round. The deadline for follow up was 31 December 1989. Screening was primarily by mammography in all trials with one or two projections. Details of the subjects included have been given in previous publications. 'H
Methods
Assume that the total observed numbers of deaths among the patients with breast cancer diagnosed after the date of randomisation in the invited and control cohorts are OJ and O, respectively. By standardisation against a suitable reference population-that is, the national cause of death statistics, the expected numbers of deaths, E, and E e, in these subcohorts-that is, patients diagnosed with breast cancer, can be estimated, and the excess deaths related to breast cancer will be OJ -E, and O, -E, respectively. As breast cancer related deaths can be assumed to occur only among the women with breast cancer, the same expressions are valid also for the total invited and control cohorts. If N, and N, are adequate expressions for the sizes and observation times-that is, person-time experience, of these total cohorts the breast cancer related excess mortality rates will be directly proportional to (OJ -E;)/N; and (O, -EJ/Ne respectively, and the relative risk (RR) of death due (directly or indirectly) to breast cancer, between the invited and the control groups, is given by:
In this study we used the national cause of death statistics" for calculation of expected numbers of deaths (E, and E e) in the breast cancer subcohorts followed up from the date of breast cancer diagnosis until 31 December 1989.
In three of the four trials (WE, Stockholm, Gothenburg) the women in the control groups were also invited to screening four to five years after randomisation. Therefore the statistical analysis in the overview" was performed according to two models. In one analysis, the "follow up model", all breast cancer deaths among women with a primary diagnosis after the date of randomisation were included. In the other, the "evaluation model", breast cancer cases diagnosed after completion of the first Larsson, Nystrom, Wall, er al round of the screening of the controls were ignored in order to reduce the diluting effect of screening in the control groups. With the mentioned deadline for observation both methods gave very similar relative risk estimates." In this study the "follow up" model was used and was compared with the relative risks for breast cancer as underlying cause of death according to the independent EPC and according to the national cause of death statistics at Statistics Sweden.
Statistical and epidemiological data analyses were performed using the QUEST software program." Expected values and relative risk estimates were calculated using the density method, where the total person-time experience of the cohort by time interval of follow up was used as a basis for estimating the mortality rates from breast cancer. Weighted relative risks and confidence intervals were calculated by Mantel-Haenszel procedures. The estimates were standardised by age at randomisation in five-year age groups.
The usual formula for the variance of the RR assuming a Poisson distribution and independence of OJ and O, is Table 1 shows the results obtained by the excess mortality method and table 2 those obtained by direct classification of causes of death by an EPC or by Statistics Sweden. The breast cancer sub cohorts consist of3756 breast cancer cases in the invited group and 2693 in the control group followed up for 18 650 and 10 605 person-years respectively -that is, from the date of breast cancer diagnosis to 31 December 1989.
Results
The relative risk estimates according to the excess mortality method were very similar to those obtained with the traditional cohort approach with cause of death classified by an EPC or by Statistics Sweden. The reduction of breast cancer related mortality was 24% in the total group according to the excess mortality method, compared with 23% and 20% respectively according to EPC and Statistics Sweden. Tables 1 and 2 show the results for the different age groups.
Discussion
The "excess mortality" concept has been derived and applied in connection with some descriptive register-based epidemiological Table 1 Breast cancer related excess mortality by age at randomisation. Number of observed (0) and expected (E) deaths in the breast cancer subgroups, number of person-years in the breast cancer cohorts (n) and in the total cohorts (N), relative riJk (RR) and 95% confidence intervals (CI studies."- 14 However, it has, to our knowledge, previously not been used in the analysis of randomised screening trials. This seems astonishing as the method is both simple and theoretically sound. For this study we used the Swedish female population as a reference, which seems natural in a country with a relatively homogeneous population. Another possibility is of course to use the whole control group, including those with breast cancer diagnosed before randomisation. However, the limited size of this reference population would increase the random uncertainty in the estimation of E, and E e , and the width of the confidence intervals. The randomised screening trials for early detection of cancer have as a rule been analysed by individual identification of causes of death in the cancer subgroups diagnosed after invitation to screening. However, regardless of whether the cause of death is determined from register data or by retrospective analysis of the medical documentation, individual cause of death identification cannot be assumed to give an absolutely true estimate of the excess mortality caused (directly or indirectly) by breast cancer. Some women with breast cancer who were classified as having died from this disease might have died from other causes, such as cardiovascular diseases, other malignant tumours, accidents etc, and the individual cause of death identification could in this way overestimate the excess mortality caused by breast cancer. Women with metastases from an unknown second primary malignancy can also be erroneously registered as having died from breast cancer. Also, deviations in the opposite direction are possible. For example, the stress caused by the diagnosis of breast cancer might increase the mortality from other causes (for instance cardiovascular disease, suicide), and side effects of treatment might cause a death that is not recorded as related to breast cancer at an individual cause of death evaluation.
The presently described indirect method for estimation of the cancer related excess mortality overcomes these shortcomings and can be regarded as a valuable supplement to the individual cause of death determination. However, the excess deaths (0; -E; and O, -E c ) in the breast cancer subcohorts were strikingly similar to the number of breast cancer deaths derived by conventional methods (table 1 and 2). Also the RRs were similar with the different methods. One exception, however, was the age group 70-74, in which the excess death method gave an RR of 0.84 compared with 0.98 and 1.05 when cause of death according to EPC and Statistics Sweden were used. A probable explanation for this discrepancy is the high prevalence of deaths from a cause other than breast cancer in these old women which makes the individual determination of cause of death more uncertain.
This study thus strongly supports the beneficial effect of mammography screening in the age group 50-69. In the age group 40--49 the effect seemed to be small in accordance with previously reported results from the overview." 
